The estimated Net Worth of Street Partners Llc Adams is at least $662 million dollars as of 5 June 2024. Street Adams owns over 40,178 units of Fusion Pharmaceuticals stock worth over $4,475,051 and over the last 11 years Street sold FUSN stock worth over $657,059,054.
Street has made over 39 trades of the Fusion Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently Street exercised 40,178 units of FUSN stock worth $865,836 on 5 June 2024.
The largest trade Street's ever made was selling 1,813,043 units of Fusion Pharmaceuticals stock on 8 August 2016 worth over $24,022,820. On average, Street trades about 315,514 units every 44 days since 2014. As of 5 June 2024 Street still owns at least 207,659 units of Fusion Pharmaceuticals stock.
You can see the complete history of Street Adams stock trades at the bottom of the page.
Street's mailing address filed with the SEC is ONE NORTH WACKER DRIVE, STE 2700, CHICAGO, IL, 60606.
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams et & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include: